These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. Gottlieb SL; Douglas JM; Foster M; Schmid DS; Newman DR; Baron AE; Bolan G; Iatesta M; Malotte CK; Zenilman J; Fishbein M; Peterman TA; Kamb ML; J Infect Dis; 2004 Sep; 190(6):1059-67. PubMed ID: 15319854 [TBL] [Abstract][Full Text] [Related]
48. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Corey L; Ashley R; Herpes; 2004 Aug; 11 Suppl 3():170A-174A. PubMed ID: 15319087 [TBL] [Abstract][Full Text] [Related]
49. Trends in herpes simplex virus type 1 and 2 infections among patients diagnosed with genital herpes in a Finnish sexually transmitted disease clinic, 1994-2002. Kortekangas-Savolainen O; Vuorinen T Sex Transm Dis; 2007 Jan; 34(1):37-40. PubMed ID: 17195754 [TBL] [Abstract][Full Text] [Related]
50. Question and answer: genital herpes. Holland R Can Med Assoc J; 1985 Mar; 132(6):615. PubMed ID: 4038907 [No Abstract] [Full Text] [Related]
51. [Frequency of genital infection by type I herpes simplex virus in women]. González-Escalada A; Prieto C; Maldonado S; Babiano MJ; Otero JR Enferm Infecc Microbiol Clin; 1999 Oct; 17(8):424. PubMed ID: 10563101 [No Abstract] [Full Text] [Related]
53. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068 [TBL] [Abstract][Full Text] [Related]
54. Acyclovir suppression to prevent recurrent genital herpes at delivery. Scott LL; Hollier LM; McIntire D; Sanchez PJ; Jackson GL; Wendel GD Infect Dis Obstet Gynecol; 2002; 10(2):71-7. PubMed ID: 12530483 [TBL] [Abstract][Full Text] [Related]
55. The scope of genital herpes among private physician patients. Robertson B Ala Med; 1984 Jan; 53(7):27-8. PubMed ID: 6731210 [No Abstract] [Full Text] [Related]
56. An update on short-course episodic and prevention therapies for herpes genitalis. Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886 [TBL] [Abstract][Full Text] [Related]
57. Changing trends of genital herpes in Kuala Lumpur, Malaysia, 1982-2008. Chiam CW; Chan YF; Sam IC Int J STD AIDS; 2010 Jun; 21(6):450-1. PubMed ID: 20606232 [No Abstract] [Full Text] [Related]
58. A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Fife KH; Almekinder J; Ofner S Sex Transm Dis; 2007 May; 34(5):297-301. PubMed ID: 16960547 [TBL] [Abstract][Full Text] [Related]
59. Genital herpes in young adults: changing sexual behaviours, epidemiology and management. Roberts C Herpes; 2005 Jun; 12(1):10-4. PubMed ID: 16026639 [TBL] [Abstract][Full Text] [Related]
60. Are genital herpes and warts really disappearing problems? Donovan B; Mindel A Aust J Public Health; 1995 Apr; 19(2):216-7. PubMed ID: 7646673 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]